ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993

RFPs Available, NIH Funding Strategies

February 18, 1994

UCLA, NYU Get Money, Near comprehensive Identification

May 30, 1975

Lung Cancer Incidence Decreases Significantly In White Males For First Time In At Least 30 Years

December 6, 1985

Cancer Vaccine RFAs Approved In Concept By NCI Advisors

July 26, 1991

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

May 21, 2004